05th August, 2020

The Corporate Relationship Department
BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai 400 001.

National Stock Exchange of India Limited
Exchange Plaza,
Bandra Kurla Complex,
Bandra East,
Mumbai 400 051.

Scrip Code: 539523
Scrip Symbol: ALKEM

Dear Sirs,


This is to intimate you that Alkem Laboratories Limited (the “Company”) has launched Favipiravir in India under the brand name “Alfluenza” for the treatment of mild to moderate COVID-19. Favipiravir has received authorization from the Drug Controller General of India (DCGI) for restricted emergency use in India. A press release in this regards is enclosed herewith.

Kindly take the same on record.

Sincerely,

For Alkem Laboratories Limited

MANISH NARANG

Digitally signed by
MANISH NARANG
Date: 2020.08.05 17:36:05 +05'30'

Manish Narang
President – Legal, Company Secretary & Compliance Officer

Encl: a/a
Alkem launches Favipiravir under the brand name Alfluenza in India for management of mild to moderate cases of COVID-19

Mumbai, 5th August, 2020: The cases of COVID-19 is increasing significantly globally and India too is affected with around 50,000 new cases being added on a daily basis. In this backdrop, Alkem Laboratories Ltd. (Alkem) has launched Favipiravir under the brand name “Alfluenza” in India for the management of mild to moderate cases of COVID-19. Favipiravir is approved by DCGI (Drug Controller General of India) for restricted emergency use in India. Restricted use entails responsible medication use where every patient must have signed informed consent before treatment initiation.

About Alkem Laboratories Ltd.
Established in 1973 and headquartered in Mumbai, Alkem (NSE: ALKEM, BSE: 539523, Bloomberg: ALKEM.IN, Reuters: ALKE.NS) is a leading Indian pharmaceutical company with global operations, engaged in the development, manufacture and sale of pharmaceutical and nutraceutical products. The Company produces branded generics, generic drugs, active pharmaceutical ingredients (APIs) and nutraceuticals, which it markets in India and International markets. With a portfolio of more than 800 brands in India, Alkem is ranked the fifth largest pharmaceutical company in India in terms of domestic sales (Source: IQVIA data March 2020). The Company also has presence in more than 40 international markets, with the United States being its key focus market.

For more information on Alkem Laboratories Ltd., please visit www.alkemlabs.com